Compare Illumina, Inc. (ILMN) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MasterCard Inc — how do they compare? Illumina, Inc. trades at $191.43 (market cap $27.94B), while MasterCard Inc trades at $539.21 (market cap $483.71B). The key difference: MasterCard Inc is far larger — about 17.3× Illumina, Inc.'s market cap, and MasterCard Inc pays a 0.64% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MA | |
|---|---|---|
Market Cap | $27.94B | $483.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $598.96 |
52-Week Low | $91.00 | $471.55 |
Enterprise Value | $29.33B | $494.45B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Mastercard (MA) trades at $541.66, down 0.36% on the day, with a bullish technical outlook and strong institutional interest. The stock exhibits robust fundamentals with revenue growth from $32.79B in 2025 to $33.9B projected for 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights AI integration in ASEAN and initiatives to expand digital payment access, reinforcing its market leadership.
The outlook remains positive with a consensus price target of $634.27 implying 17% upside, supported by 79% analyst buy ratings. Key risks include payment disruption from stablecoins and competitive pressures, but Mastercard's innovation and profitability provide a solid foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
